{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:07:58Z","timestamp":1790874478715,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet Med"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The pathophysiology of chronic kidney disease (CKD) and type 2 diabetes (T2D) is multifactorial and associated with a plethora of underlying conditions and complications. Their link is reciprocal and understanding its nature, particularly over time, could improve the health of many.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective study was conducted to examine the development of the two main components of CKD (urine albumin\/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR)) over 24\u2009years (2001\u20132024) in a sample of 718 individuals with a diagnosis of T2D. Longitudinal modelling was conducted to examine the rate of change of ACR and eGFR over the 24\u2009years, as well as whether sex, smoking status, glycated haemoglobin (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI) influenced that rate of change in both our total sample and three sub\u2010groups (no CKD, CKD with increased ACR and preserved eGFR, and CKD with increased ACR and reduced eGFR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, 428 (59.6%) patients were male while 290 (40.4%) were female. Mean age at baseline was 56.6\u2009\u00b1\u200912.4\u2009years. Mean follow\u2010up period was 16.4\u2009\u00b1\u20092.1\u2009years. 451 (62.8%) patients had a normal ACR and eGFR \u226560\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      , no CKD. At 24\u2010year follow\u2010up, 196 (43%) of these patients had progressed to an ACR &gt;3\u2009mg\/mmol and\/or eGFR&lt;60\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      , developing CKD. At final follow\u2010up, 282 patients were still alive. In the whole cohort, 10 (1.4%) patients progressed to end\u2010stage kidney disease eGFR&lt;15\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      For the whole cohort ACR increased exponentially, while eGFR decreased linearly by 1.02\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      per year.\n                    <\/jats:p>\n                    <jats:p>\n                      For ACR: SBP (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u20090.36, 95% CI [0.24, 0.48]) and DBP (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u20090.40, 95% CI [0.16, 0.64]) were the only significant independent predictors of ACR progression particularly in the sub\u2010group with increased ACR and preserved eGFR.\n                    <\/jats:p>\n                    <jats:p>\n                      For eGFR: Female sex (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22123.79, 95% CI [1.96, 5.63]), SBP (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22120.12, 95% CI [\u22120.17, \u22120.06]), DBP (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22120.19, 95% CI [\u22120.08, \u22120.31]), HbA1c (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22121.17, 95% CI [\u22120.63, \u22121.71]), baseline cholesterol (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u20090.86, 95% CI [0.29, 1.43]) and smoking (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22122.05, 95% CI [\u22123.80, \u22121.30]) were significant independent predictors of eGFR progression, but only in the non\u2010CKD at baseline sub\u2010group.\n                    <\/jats:p>\n                    <jats:p>\n                      At the end of follow\u2010up 436 (60%) of people had died including 219 (48.6%) of the patients with no CKD at baseline, compared to 158 (76.7%) of people with increased urine ACR\/preserved eGFR and 59 (96.7%) of those with increased urine ACR and reduced eGFR, with 10\u2009year mortality rates of 6.6%, 14.5% and 26.6%, respectively. In the whole cohort only 10 (1.4%) patients progressed to end\u2010stage kidney disease (eGFR&lt;15\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study revealed several factors that are associated with accelerated progression of CKD over 20\u2009+\u2009years, including female sex and current\/previous smoking. At baseline, the group with ACR &gt;3\u2009mg\/mmol exhibited the highest rate of ACR increase. Multiple factors influenced eGFR decrease in those with baseline eGFR \u226560\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      . Mortality rate was profoundly influenced by historical CKD status.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dme.70193","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:59:36Z","timestamp":1767182376000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Progression of albumin\/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) over 24\u2009years in people with type 2 diabetes. Drivers, potential protectors and associated mortality"],"prefix":"10.1111","volume":"43","author":[{"given":"Andreas","family":"Matheou","sequence":"first","affiliation":[{"name":"University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orestis","family":"Zavlis","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"White","sequence":"additional","affiliation":[{"name":"University of Newcastle  Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Salford Royal Hospital Northern Care Alliance NHS Foundation Trust  Salford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Warner\u2010Levy","sequence":"additional","affiliation":[{"name":"University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Warner\u2010Levy","sequence":"additional","affiliation":[{"name":"University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Wilkins","sequence":"additional","affiliation":[{"name":"University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hellena","family":"Habte\u2010Asres","sequence":"additional","affiliation":[{"name":"Kings College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Lay","sequence":"additional","affiliation":[{"name":"University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Shalamanova","sequence":"additional","affiliation":[{"name":"Manchester Metropolitan University  Manchester UK"},{"name":"Department of Diabetes and Endocrinology Salford Royal Hospital  Salford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-2026","authenticated-orcid":false,"given":"Martin","family":"Whyte","sequence":"additional","affiliation":[{"name":"Kings College London  London UK"},{"name":"University of Surrey  Guildford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gibson","sequence":"additional","affiliation":[{"name":"University of Manchester  Manchester UK"},{"name":"Department of Renal Medicine, Salford Royal Hospital Northern Care Alliance NHS Foundation Trust  Salford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Kalra","sequence":"additional","affiliation":[{"name":"University of Manchester  Manchester UK"},{"name":"Department of Renal Medicine, Salford Royal Hospital Northern Care Alliance NHS Foundation Trust  Salford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Heald","sequence":"additional","affiliation":[{"name":"University of Manchester  Manchester UK"},{"name":"Department of Renal Medicine, Salford Royal Hospital Northern Care Alliance NHS Foundation Trust  Salford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0001-y"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.18"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32064-5"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15260"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59184-3"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01463-9"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28780"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01202-x"},{"key":"e_1_2_15_10_1","unstructured":"Northern Care Alliance Research and Innovation.What is Salford Integrated Record?2021Accessed December 1 2024.https:\/\/www.ncaresearch.org.uk\/news\/what\u2010is\u2010salford\u2010integrated\u2010record\/"},{"key":"e_1_2_15_11_1","unstructured":"Greater Manchester We are better together GM Care Record. Accessed December 1 2024.https:\/\/gmwearebettertogether.com\/research\u2010and\u2010planning\u2010using\u2010the\u2010gm\u2010care\u2010record\u2010and\u2010the\u2010secure\u2010data\u2010environment\/"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.2000.10474335"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-0919-5_37"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176344136"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0049124104268644"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-51862-0.50018-6"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.2307\/2529876"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111349"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.5049\/EBP.2022.20.2.39"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008070667"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.07.016"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.08.026"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3695"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000276"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000001000"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21478"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101544"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijheh.2011.03.004"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S451628"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.12.018"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-005-0180-4"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2023.03.004"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02496.x"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.70193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dme.70193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.70193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:59:26Z","timestamp":1781326766000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.70193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/dme.70193"],"URL":"https:\/\/doi.org\/10.1111\/dme.70193","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"2025-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70193"}}